Impact News +++ ANLEIHEN-Woche #KW34 – 2025: Energiekontor, JDC, The Platform Group, Aream, LEEF, Dt. Rohstoff,... (Anleihen-Finder) +++ PLATFORM GROUP Aktie +4,84%

EYEPOINT Aktie

>EYEPOINT Aktienkurs

10.035 EUR +0.4% (Tradegate)

Ask: 10.36 EUR / 160 Stück

Bid: 9.834 EUR / 170 Stück

Tagesumsatz: 139 Stück

Realtime Kurs von 8 bis 22 Uhr!

EYEPOINT Aktie über LYNX handeln

Intraday

1 Jahr

>EYEPOINT Performance

1 Woche: +9,6%

1 Monat: +11,2%

3 Monate: +101,9%

6 Monate: +62,7%

1 Jahr: +23,8%

laufendes Jahr: +40,9%

>EYEPOINT Aktie

Name:

EYEPOINT PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US30233G2093 / A2QJRU

Symbol/ Ticker:

PV3B (Frankfurt) / EYPT (NASDAQ)

Kürzel:

FRA:PV3B, ETR:PV3B, PV3B:GR, NASDAQ:EYPT

Index:

Webseite:

https://eyepointpharma.co..

Profil:

EyePoint Pharmaceuticals Inc. is a specialty bioph..
>Volltext..

Marktkapitalisierung:

653.05 Mio. EUR

Unternehmenswert:

454.61 Mio. EUR

Umsatz:

44.54 Mio. EUR

EBITDA:

-160.6 Mio. EUR

Nettogewinn:

-150.51 Mio. EUR

Gewinn je Aktie:

-2.3 EUR

Schulden:

18.72 Mio. EUR

Liquide Mittel:

61.05 Mio. EUR

Operativer Cashflow:

-163.56 Mio. EUR

Bargeldquote:

7.71

Umsatzwachstum:

-6.35%

Gewinnwachstum:

-83.68%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

EYEPOINT

Letzte Datenerhebung:

22.08.25

>EYEPOINT Kennzahlen

Aktien/ Unternehmen:

Aktien: 68.93 Mio. St.

Frei handelbar: 87.44%

Leerverk. Aktien: 10.12%

Rückkaufquote: -21.68%

Mitarbeiter: 165

Umsatz/Mitarb.: 0.23 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 201.26%

Bewertung:

KGV: -

KGV lG: -

KUV: 14.91

KBV: 3.22

PEG-Ratio: -0.08

EV/EBITDA: -

Rentabilität:

Bruttomarge: 94.1%

Gewinnmarge: -337.93%

Operative Marge: -364.27%

Managementeffizenz:

Gesamtkaprendite: -56.09%

Eigenkaprendite: -73.95%

>EYEPOINT Peer Group

Es sind 601 Aktien bekannt.

>EYEPOINT Chart & Kurs - NASDAQ

>EYEPOINT News

18.08.25 - 22:03

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....

06.08.25 - 23:12	EyePoint (EYPT) Q2 Revenue Drops 44% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 22:12	EyePoint signals 2026 LUGANO Phase III data and NDA filing for DURAVYU amid accelerated trial enrollment (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 16:00	EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
	EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -26.87% and -32.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

06.08.25 - 13:36

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire EN)

WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Thursday, August 13, 2025 at 10:00 a.m. ET....

06.08.25 - 13:03	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire EN)
	– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized –...

05.08.25 - 16:54	EyePoint Pharmaceuticals Q2 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.25 - 13:03

EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire EN)

WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments....

29.07.25 - 13:03	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration (GlobeNewswire EN)
	– LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community –...

16.07.25 - 13:03

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....

16.06.25 - 13:03

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....

28.05.25 - 22:03	EyePoint Announces Participation at Upcoming Investor Conferences (GlobeNewswire EN)
	WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate in fireside chats at the following upcoming investor conferences:...

27.05.25 - 13:03	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration (GlobeNewswire EN)
	– Over 400 patients enrolled and randomized over a seven-month period, driven by strong physician and patient interest –...

20.05.25 - 01:01	Insiderhandel: Aufsichtsrat kauft Aktien von Eyepoint Pharmaceuticals im Wert von 29050 USD (Insiderkauf)
	Zaderej, Karen L. - Aufsichtsrat - Tag der Transaktion: 2025-05-16...

20.05.25 - 01:01	Insiderhandel: Aufsichtsrat kauft Aktien von Eyepoint Pharmaceuticals im Wert von 29950 USD (Insiderkauf)
	Zaderej, Karen L. - Aufsichtsrat - Tag der Transaktion: 2025-05-19...

16.05.25 - 13:03

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4)....

16.05.25 - 00:01	Insiderhandel: Aufsichtsrat kauft Aktien von Eyepoint Pharmaceuticals im Wert von 27350 USD (Insiderkauf)
	Zaderej, Karen L. - Aufsichtsrat - Tag der Transaktion: 2025-05-15...

16.05.25 - 00:01	Insiderhandel: Aufsichtsrat kauft Aktien von Eyepoint Pharmaceuticals im Wert von 27100 USD (Insiderkauf)
	Zaderej, Karen L. - Aufsichtsrat - Tag der Transaktion: 2025-05-14...

07.05.25 - 20:54	Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.25 - 16:30	EyePoint Pharmaceuticals (EYPT) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
	The headline numbers for EyePoint Pharmaceuticals (EYPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ein Politiker verschweigt oft auch das, was er nicht weiß. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram